INTRODUCTION
============

Laparoscopic sleeve gastrectomy (LSG) is the most commonly performed bariatric procedure in the United States, favored for its excess weight loss, resolution of comorbidities, and low complication rate.^[@B1]^ Serious complications associated with LSG include postoperative leaks and hemorrhage from the staple line. The reported incidence of staple line hemorrhage is up to 3%.^[@B2]^ The median additional cost per bleed is approximately \$5261 (range \$1879-\$49,350), with the majority attributable to prolonged hospital stay.^[@B3]^

Staple line reinforcement (SLR)---using biologic or synthetic buttressing or by oversewing the staple line---is used as a strategy to decrease the incidence of both leaks and hemorrhage. However, the effectiveness of these methods in reducing the incidence of hemorrhage POB is not well defined.^[@B4],[@B5]^ Although various studies have assessed the impact of these techniques on the safety of LSG, the results have been controversial. Using a large multicenter dataset, this study aims to determine the incidence, consequences, and factors associated with POB after LSG. We also aim to compare the risk-adjusted rates of POB among the various accepted methods of SLR.

METHODS
=======

We selected all patients undergoing an LSG from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP), participant user file (PUF) dataset for admission year 2015. The MBSAQIP is a joint venture by the American College of Surgeons and the American Society for Metabolic and Bariatric Surgery to achieve a national standard for bariatric surgery. Part of the accreditation status ensures collection of high-quality clinical and outcome data. The MBSAQIP PUF is a Health Insurance Portability and Accountability Act compliant data file containing information from all participating centers across the country for research purposes.^[@B6]^ The 2015 PUF contains demographic, clinical, operative, and outcome information from more than 160,000 patients from more than 742 centers across the United States. The dataset does not contain any identifying information for patients, surgeons, or facilities, and secondary data analysis was exempt from review by the Institutional Review Board at the University of Maryland School of Medicine.

Patients undergoing an LSG were identified by a *Current Procedural Terminology* (CPT) procedure code of 43775. We excluded patients at extremes of ages (age \< 10 y and \> 80 y). Demographic information included age, ethnicity, and sex. Biometric measurements included weight and body mass index (BMI). Preoperative clinical information included comorbid conditions, medication use, and history of certain illnesses and procedures. Intraoperative variables included concurrent procedures, length of operation, assistant\'s level of training, size of bougie used, conversion to open procedure, use of robotic technology, and method of staple line treatment. Staple line treatment included no treatment (NT), suture oversewing (OVERSEW), buttressing by a commercial product (BUTTRESS), and both buttress and oversew (COMBINATION).

The primary outcome variable was POB, defined as the need for a blood transfusion within 72 h of operation or any unplanned procedure (including reoperation, unplanned endoscopy, and interventional radiology) performed for the purposes of "bleeding." We chose this definition of POB to detect only those with clinically significant bleeding events. Patients who had POB who did not require any intervention (transfusion or procedure) were not captured in the database and are not included in the outcome analysis. Other outcome variables included postoperative length of hospital stay (LOS), in-hospital mortality, 30-d mortality, 30-d complications, discharge to facility, and readmission within 30 d.

We calculated and tabulated means and standard deviations (SDs) for continuous variables and frequency with proportions for categorical ones. To determine factors associated with POB, we performed bivariate analysis using the χ^2^ test and Student\'s *t* test when appropriate. All variables that were significant on bivariate analysis (*P* \< .05), and those that were clinically relevant were selected for the multivariable model. Multivariable logistic regression was used to determine the independent effect of staple line treatment on POB. The NT group was compared with each of the other 3 treatment groups (OVERSEW, BUTTRESS, and COMBINATION). Separate multivariable models were used to compare the effect of OVERSEW alone versus BUTTRESS alone, OVERSEW versus COMBINATION, and BUTTRESS versus COMBINATION. Bonferroni corrections were applied. The Hosmer-Lemeshow Goodness of Fit was used to test for model fit.^[@B7]^ All analyses were performed using STATA Version 13 (Stata Corp, College Station, TX, USA).

RESULTS
=======

A total of 98,142 patients undergoing LSG were selected for analysis. The mean age was 44.5 y (SD ± 12 y), and 79% of the population were women; 73.5% were reported to be of white ethnicity. The mean BMI was 45.1 kg/m^2^ (SD 8.3). Comorbid conditions were expectedly frequent, with the most common being hypertension requiring medication (48%) followed by gastroesophageal reflux disease requiring medication (29%), diabetes mellitus (23%), and hyperlipidemia (23%). The mean operative time was 78 min (SD ± 39) with 50% of operations performed between 52 and 94 min. Most used a bougie size less than 38Fr (55%). A midlevel provider was the assistant in 37% of operations, and a resident was present in 17%. No staple line treatment was used in 23% of patients, while OVERSEW alone as used in 10%, BUTTRESS in 54%, and COMBINATION in 13% (**[Table 1](#T1){ref-type="table"}**).

###### 

Demographic and Clinical Characteristics of Patients Who Sustained a Postoperative Bleeding Event Versus Those Who Did Not, From the MBSAQIP

  A: Demographics                                                                                    
  ------------------------ --------------------------- --------------- ------------- --------------- --------
  Age (years)              \<30                        10,800 (11.1)   28 (4.5)      10,828 (11.0)   \<.001
                           30--39                      24,451 (25.1)   121 (19.4)    24,572 (25.0)   
                           40--49                      28,480 (29.2)   180 (28.9)    28,660 (29.2)   
                           50--59                      22,170 (22.7)   165 (26.5)    22,335 (22.8)   
                           ≥60                         11,609 (11.9)   129 (20.7)    11,738 (12.0)   
                           Missing                     9 (0.0)         0 (0)         9 (0.0)         
  Sex                      Male                        20,459 (21.0)   155 (24.9)    20,614 (21.0)   .017
                           Female                      77,060 (79.0)   468 (75.1)    77,528 (79.0)   
  Race                     American Indian             342 (0.4)       1 (0.2)       343 (0.4)       .245
                           Asian                       450 (0.5)       4 (0.6)       454 (0.5)       
                           Black or African American   17,556 (18.0)   116 (18.6)    17,672 (18.0)   
                           Native Hawaiian             204 (0.2)       0 (0.0)       204 (0.2)       
                           White                       71,685 (73.5)   469 (75.3)    72,154 (73.5)   
                           Missing                     7,282 (7.5)     33 (5.3)      7,315 (7.5)     
  Hispanic ethnicity       Yes                         11,773 (12.1)   70 (11.2)     11,843 (12.1)   .619
                           No                          75,568 (77.5)   493 (79.1)    76,061 (77.5)   
                           Missing                     10,178 (10.5)   60 (9.6)      10,238 (10.4)   
  BMI category (kg/m^2^)   \<35                        4,073 (4.2)     31 (5.0)      4,104 (4.2)     .308
                           35--40                      22,668 (23.3)   167 (26.8)    22,835 (23.4)   
                           40--50                      48,989 (50.2)   292 (46.87)   49,281 (50.2)   
                           50--70                      19,706 (20.2)   124 (19.90)   19,830 (20.2)   
                           \>70                        1,363 (1.4)     6 (0.96)      1,369 (1.4)     
                           Missing                     719 (0.7)       3 (0.48)      722 (0.7)       

  B: Preoperative Factors                                                                                                                     
  --------------------------------------------------------------------- --------------------- --------------- --------------- --------------- ---------
  GERD requiring medication                                             Yes                   28,111 (28.8)   240 (38.5)      28,351 (28.9)   \<.001
  No                                                                    69,408 (71.2)         383 (61.5)      69,791 (71.1)                   
  Limited ambulation                                                    Yes                   1,753 (1.8)     24 (3.6)        1,777 (1.8)     \<.001
  No                                                                    95,766 (98.2)         599 (96.2)      96,365 (98.2)                   
  History of myocardial infarction                                      Yes                   1,162 (1.2)     12 (1.9)        1,1174 (1.2)    .093
  No                                                                    96,357 (98.8)         611 (98.1)      96,968 (98.8)                   
  History of cardiac surgery                                            Yes                   1,097 (1.1)     24 (3.9)        1,121 (1.1)     \<.001
  No                                                                    96,422 (98.9)         599 (96.2)      97,021 (98.9)                   
  Previous PCI/PTCA                                                     Yes                   1,861 (1.9)     26 (4.2)        1,887 (1.9)     \<.001
  No                                                                    95,658 (98.1)         597 (95.8)      96,255 (98.1)                   
  Preoperative hypertension requiring medication                        Yes                   46,362 (47.5)   391 (62.8)      46,753 (47.6)   \<0.001
  No                                                                    51,157 (52.5)         232 (37.2)      51,389 (52.4)                   
  Number of hypertension medications                                    0                     219 (0.2)       0 (0.00)        219 (0.2)       \<.001
  1                                                                     21,413 (22.0)         142 (22.8)      21,555 (22.0)                   
  2                                                                     15,772 (16.2)         148 (23.8)      15,920 (16.2)                   
  3+                                                                    60,115 (61.6)         333 (53.5)      60,448 (61.6)                   
  Preoperative therapeutic anticoagulation                              Yes                   2,098 (2.2)     56 (9.0)        2,154 (97.8)    \<.001
  No                                                                    95,421 (97.9)         567 (91.0)      95,988 (97.8)                   
  Preoperative hyperlipidemia                                           Yes                   22,449 (23.0)   217 (34.8)      22,666 (23.1)   \<.001
  No                                                                    75,070 (77.0)         406 (65.2)      75,476 (76.9)                   
  Preoperative deep venous thrombosis                                   Yes                   1,466 (1.5)     18 (2.9)        1,484 (1.5)     .005
  No                                                                    96,053 (98.5)         605 (97.1)      96,658 (98.5)                   
  Preoperative venous stasis                                            Yes                   876 (0.9)       10 (1.6)        886 (0.9)       .063
  No                                                                    96,643 (99.1)         613 (98.4)      97,256 (99.1)                   
  Preoperative dialysis                                                 Yes                   303 (0.3)       5 (0.8)         308 (0.3)       .029
  No                                                                    97,216 (99.7)         618 (99.2)      97,834 (99.7)                   
  Preoperative renal insufficiency                                      Yes                   615 (0.6)       18 (2.9)        633 (0.6)       \<.001
  No                                                                    96,904 (99.4)         605 (97.1)      97,509 (99.4)                   
  Previous surgery (obesity-related or foregut surgery)                 Yes                   6,376 (6.5)     47 (7.5)        6,423 (6.5)     .312
  No                                                                    91,143 (93.5)         576 (92.4)      91,719 (93.5)                   
  Diabetes mellitus                                                     Yes                   22,167 (22.7)   207 (33.2)      22,374 (22.8)   \<.001
                                                                        No                    75,352 (77.3)   416 (66.8)      75,768 (77.2)   
  Smoked within 1 year                                                  Yes                   8,584 (8.8)     60 (9.6)        8,644 (8.8)     .467
  No                                                                    88,935 (91.2)         563 (90.4)      89,498 (91.2)                   
  Presurgical functional status                                         Independent           96,553 (99.0)   611 (98.1)      97,164 (99.0)   .055
  Partially dependent                                                   588 (0.6)             8 (1.3)         596 (0.6)                       
                                                                        Totally dependent     378 (0.4)       4 (0.6)         382 (0.4)       
  History of COPD                                                       Yes                   1,575 (1.6)     25 (4.0)        1,600 (1.6)     \<.001
                                                                        No                    95,944 (98.4)   598 (96.0)      96,542 (98.4)   
  Oxygen dependence                                                     Yes                   597 (0.6)       12 (1.9)        609 (0.6)       \<.001
  No                                                                    96,922 (99.4)         611 (98.1)      97,533 (99.4)                   
  History of pulmonary embolism (posttreatment)                         Yes                   1,044 (1.1)     16 (2.6)        1,060 (1.1)     \<.001
  No                                                                    96,475 (98.9)         607 (97.4)      97,082 (98.9)                   
  Preoperative obstructive sleep apnea requiring CPAP/BiPAP             Yes                   33,680 (34.5)   275 (44.1)      33,955 (34.6)   \<.001
  No                                                                    63,839 (65.5)         348 (66.9)      64,187 (65.4)                   
  Preoperative steroid/immuno-suppressant use for a chronic condition   Yes                   1,591 (1.6)     16 (2.6)        1,607 (1.6)     .066
  No                                                                    95,928 (98.4)         607 (97.4)      96,535 (98.4)                   
  Preoperative IVC filter                                               Yes                   899 (0.9)       8 (1.3)         907 (0.9)       .346
  No                                                                    96,620 (99.1)         615 (98.7)      97,235 (99.0)                   
  ASA classification principle operative procedure                      I No disturbance      528 (0.5)       3 (0.5)         531 (0.5)       \<.001
  II Mild disturbance                                                   25,336 (26.0)         124 (19.9)      25,460 (25.9)                   
  III Severe disturbance                                                68,099 (69.8)         437 (70.1)      68,536 (69.8)                   
                                                                        IV Life threatening   3,259 (3.3)     57 (9.2)        3,316 (3.4)     
                                                                        V Moribund            4 (0.0)         1 (0.2)         5 (0.0)         
                                                                        None assigned         293 (0.3)       1 (0.2)         294 (0.3)       
  Preoperative hematocrit                                               \<21                  138 (0.1)       1 (0.2)         139 (0.1)       \<.001
                                                                        21--30                237 (0.2)       13 (2.1)        250 (0.3)       
                                                                        30--36                6,209 (6.4)     68 (10.9)       6,277 (6.4)     
                                                                        36--45                70,495 (72.3)   407 (65.3)      70,902 (72.2)   
                                                                        \>45                  11,324 (11.6)   81 (13.0)       11,405 (11.6)   
                                                                        Unknown               9,116 (9.4)     53 (8.5)        9,169 (9.3)     
  Preoperative albumin less than                                        Yes                   374 (0.4)       6 (1.0)         380 (0.4)       .020
  3 mg/dL                                                               No                    97,145 (99.6)   617 (99.0)      97,762 (99.6)   

  C: Intraoperative Variables                                                                                             
  ------------------------------------------------------- --------------- --------------- --------------- --------------- --------
  Robotic approach                                        Yes             5,843 (6.0)     33 (5.3)        5,876 (6.0)     .466
                                                          No              91,676 (94.0)   590 (94.7)      92,266 (94.0)   
  Approach converted to open                              Yes             57 (0.1)        9 (1.4)         66 (0.1)        \<.001
  No                                                      97,462 (99.9)   614 (98.6)      98,076 (99.9)                   
  Reoperation revision/conversion                         Yes             5,544 (5.7)     42 (6.7)        5,586 (5.7)     .257
  No                                                      91,975 (94.3)   581 (93.3)      92,556 (94.3)                   
  Drain placed at time of operation                       Yes             19,748 (20.3)   163 (26.2)      19,911 (20.3)   \<.001
  No                                                      77,771 (79.8)   460 (73.8)      78,231 (79.7)                   
  Swallow study performed day of or day after procedure   Yes, routine    41,846 (42.9)   243 (39.0)      42,089 (42.9)   .001
  Yes, selective                                          1,359 (1.4)     19 (3.1)        1,378 (1.4)                     
  No                                                      54,314 (55.7)   361 (58.0)      54,675 (55.7)                   
  Concurrent procedure                                    None            65,191 (66.9)   406 (65.2)      65,597 (66.8)   .006
  Liver biopsy                                            5,902 (6.1)     57 (9.2)        5,959 (6.1)                     
  Hiatal hernia repair                                    22,209 (22.8)   125 (20.1)      22,334 (22.8)                   
  Cholecystectomy                                         1,353 (1.4)     12 (1.9)        1,365 (1.4)                     
  Band removal                                            2,864 (2.9)     23 (3.7)        2,887 (2.9)                     
  Assistant level                                         Resident        16,472 (16.9)   121 (19.4)      16,593 (16.9)   .233
  Fellow                                                  7,578 (7.8)     59 (9.5)        7,637 (7.8)                     
  PA/NP/RNF                                               35,725 (36.6)   222 (35.6)      35,947 (36.6)                   
  Attending                                               16,135 (16.6)   98 (15.7)       16,233 (16.5)                   
  Attending non-bariatric                                 6,157 (6.3)     33 (5.3)        6,190 (6.3)                     
  None                                                    15,452 (15.9)   90 (14.5)       15,542 (15.8)                   
  Bougie size                                             \< 38Fr         54,066 (55.4)   341 (54.7)      54,407 (55.4)   .302
  ≥ 38Fr                                                  39,212 (40.2)   247 (39.7)      39,459 (40.2)                   
  Missing                                                 4,241 (4.4)     35 (5.6)        4,276 (4.4)                     
  Staple line treatment                                   No treatment    22,420 (23.0)   181 (29.1)      22,601 (23.0)   .005
  Oversew alone                                           9,864 (10.1)    68 (10.9)       9,932 (10.1)                    
  Buttress                                                52,654 (54.0)   304 (48.8)      52,958 (54.0)                   
  Combination of buttress and oversew                     12,576 (12.9)   70 (11.2)       12,646 (12.9)                   

ASA, American Society of Aanesthesiology; BiPAP, bilevel positive airway pressure; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CPAP, continuous positive airway pressure; GERD, gastroesophageal reflux disease; IVC, inferior vena cava; NP, nurse practitioner; PA, physician assistant; PCI, percutaneous coronary intervention; POB, postoperative bleeding; PTCA, percutaneous transluminal coronary angioplasty; RNF, Registered Nurse First Assistant.

Values given as n (%).

A total of 623 (0.63%) patients had POB. Management of POB included reoperation in 181 (29.1%) patients and unplanned endoscopy in 34 (5.5%) patients. Patients with POB received a mean of 2.6 U of blood (range 1 to 12 U). The incidence of POB was 0.80% for the NT group, 0.68% for the OVERSEW group, 0.57% for the BUTTRESS group, and 0.55% for the COMBINATION group. **[Table 2](#T2){ref-type="table"}** depicts outcomes for patients with POB versus for patients without POB. Patients with POB had a significantly longer median LOS (3 vs 2 d), were more likely to suffer a 30-d complication (13.8% vs 1.3%), were more likely to be discharged to a facility rather than to home (4.01% vs 0.47%), and had higher mortality (1.12% vs 0.08%) (all *P*-values \< .001).

###### 

Bivariate Comparison of Outcomes for Patients Who Sustained a Postoperative Bleed After Laparoscopic Sleeve Gastrectomy Versus Those Who Did Not, From the MBSAQIP

  Outcome                                                        No POB          POB           Total           *P* Value
  -------------------------------------------------------------- --------------- ------------- --------------- -----------------------------------------
  Length of stay: 0--1 days                                      46,939 (48.2)   35 (5.7)      46,974 (47.9)   \<.001
  2 days                                                         40,957 (42.0)   79 (12.7)     41,036 (41.9)   
  3--7 days                                                      8,971 (9.21)    467 (75.3)    9,438 (9.63)    
  \>7 days                                                       560 (0.57)      39 (6.29)     599 (0.61)      
  Length of stay, median (IQR)                                   2 (1--2)        3 (3--3)      2 (1--2)        \<.001[\*](#TF2-1){ref-type="table-fn"}
  Discharged to facility                                         455 (0.47)      25 (4.01)     480 (0.49)      \<.001
  In-hospital mortality                                          19 (0.02)       7 (1.12)      26 (0.03)       \<.001
  30-day postsurgery mortality                                   81 (0.08)       7 (1.12)      88 (0.09)       \<.001
  Unplanned readmission within 30 days                           431 (0.44)      135 (21.67)   566 (0.58)      \<.001
  Acute renal failure requiring hemodialysis                     54 (0.06)       12 (1.93)     66 (0.07)       \<.001
  Intraoperative or postoperative cardiac arrest requiring CPR   26 (0.03)       12 (1.93)     38 (0.04)       \<.001
  Intraoperative or postoperative cerebrovascular incident       9 (0.01)        3 (0.48)      12 (0.01)       \<.001
  Postoperative deep incisional SSI                              27 (0.03)       1 (0.16)      28 (0.03)       .050
  Postoperative superficial SSIs                                 239 (0.25)      5 (0.80)      244 (0.25)      \<.001
  Postoperative organ space SSIs                                 174 (0.18)      14 (2.25)     188 (0.19)      \>.001
  Wound disruption                                               20 (0.02)       4 (0.64)      24 (0.02)       \<.001
  Postoperative ventilator requirement \> 48 hours               51 (0.05)       14 (2.25)     65 (0.07)       \<.001
  Intraoperative or postoperative myocardial infarction          27 (0.03)       3 (0.48)      30 (0.03)       \<.001
  Pulmonary embolism                                             87 (0.09)       5 (0.80)      92 (0.09)       \<.001
  Progressive renal insufficiency (not requiring hemodialysis)   62 (0.06)       11 (1.77)     73 (0.07)       \<.001
  Postoperative sepsis (if occurred)                             76 (0.08)       12 (1.93)     88              \<.001
  Postoperative septic shock                                     31 (0.03)       8 (1.28)      39 (0.04)       \<.001
  Unplanned intubation                                           99 (0.10)       25 (4.01)     124 (0.13)      \<.001
  Postoperative UTI                                              271 (0.28)      5 (0.80)      276 (0.28)      .048
  Postoperative venous thrombosis requiring treatment            170 (0.17)      7 (1.12)      177 (0.18)      \<.001
  Postoperative pneumonia                                        129 (0.13)      8 (1.28)      137 (0.14)      \<.001
  Any complication                                               1,264 (1.30)    86 (13.8)     1,350 (1.38)    \<.001

Length of stay variables are postoperative length of stay. CPR, cardiopulmonary resuscitation; IQR, interquartile range; MBSAQIP, Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program; SSI, surgical site infection; UTI, urinary tract infection.

\* Wilcoxon rank sum test.

On bivariate analysis, several preoperative and operative factors were associated with POB ([Table 1](#T1){ref-type="table"}). Multivariable analysis (**[Table 3](#T3){ref-type="table"}**) revealed factors associated with an increased likelihood of POB included higher age (OR 2.02, 95% CI 1.27--3.21 for age \> 60 y vs \< 30 y), gastroesophageal reflux disease requiring medication (OR 1.23, 95% CI 1.04--1.47), hypertension (OR 1.33, 95% CI 1.10--1.62), history of renal failure (OR 2.10, 95% CI 1.20--3.68), preoperative therapeutic anticoagulation (OR 3.20, 95% CI 2.26--4.55), undergoing a liver biopsy (OR 1.41, 95% CI 1.05, 1.89), conversion to open (OR 17.7, 95% CI 8.00--39.1), and placement of a drain (OR 1.36, 95% CI 1.12--1.65). However, higher weight (OR 0.98, 95% CI 0.96--0.99 for every 10-kg increase) and higher preoperative hematocrit (OR 0.15, 95% CI 0.08--0.28 for hematocrit of \> 45% vs \< 30%) were both associated with a decreased likelihood of POB.

###### 

Factors Associated With Bleeding From Multivariable Logistic Regression Analysis

  Variable                                   Categories             Odds Ratio   95% CI       *P* Value
  ------------------------------------------ ---------------------- ------------ ------------ -----------
  Staple line treatment                      No treatment           1.00         --           --
                                             Oversew alone          0.73         0.54--0.98   .040
                                             Buttress               0.70         0.57--0.84   \<.001
                                             Combination            0.66         0.50--0.89   \<.001
  Age (years)                                \<30                   1.00         --           --
                                             30--39                 1.64         1.06--2.52   .025
                                             40--49                 1.82         1.19--2.78   .006
                                             50--59                 1.81         1.17--2.81   .008
                                             \>60                   2.02         1.27--3.21   .003
  Weight                                     Every 10-kg increase   0.98         0.96--0.99   .009
  Preoperative hematocrit level              \<30                   1.00         --           --
  30--36                                     0.22                   0.11--0.42   \<.001       
                                             36--45                 0.13         0.07--0.24   \<.001
                                             \>45                   0.15         0.08--0.28   \<.001
  GERD requiring medications                 Yes                    1.23         1.04--1.47   .018
  HTN requiring medications                  Yes                    1.33         1.10--1.62   .004
  History of renal insufficiency             Yes                    2.10         1.20--3.68   .009
  Preoperative therapeutic anticoagulation   Yes                    3.20         2.26--4.55   \<.001
  Liver biopsy                               Yes                    1.41         1.05--1.89   .022
  Converted to open                          Yes                    17.7         8.00--39.1   \<.001
  Drain placed                               Yes                    1.36         1.12--1.65   .002

CI, confidence interval; GERD, gastroesophageal reflux disease; HTN, hypertension.

Model additionally adjusted for sex, revisional surgery, functional status, preoperative percutaneous cardiac intervention, prior cardiac surgery, history of deep vein thrombosis or pulmonary embolism, prior foregut surgery, history of hyperlipidemia, diabetes, history of chronic obstructive pulmonary disease, oxygen dependency, robotic approach, assistant level of training, preoperative albumin level, leak testing, and other concurrent procedures.

Staple line treatment was an independent factor associated with POB. OVERSEW (OR 0.73, 95% CI 0.54--0.98), BUTTRESS (OR 0.70, 95% CI 0.57--0.84), and COMBINATION (OR 0.66, 95% CI 0.50--0.89) were significantly protective against bleeding compared with an untreated staple line. In separate multivariable models when staple line treatments were compared, no difference was found for OVERSEW versus BUTTRESS (OR 0.95, 95% CI 0.71--1.26), OVERSEW versus COMBINATION (OR 0.91, 95% CI 0.63--1.32), or BUTTRESS versus COMBINATION (OR 0.96, 95% CI 0.73--1.26) (**[Figure 1](#F1){ref-type="fig"}**).

![Multivariable comparison of various staple line treatment methods and postoperative bleeding. **A.** Comparison of postoperative bleeding between untreated staple lines and the various staple line reinforcement techniques. (adjusted odds ratios and 95% confidence intervals provided.) **B.** Comparison of postoperative bleeding between oversew and buttress techniques of staple line reinforcement. (Adjusted odds ratios and 95% confidence intervals provided.)](jls0201637340001){#F1}

DISCUSSION
==========

The impact of SLR on POB is controversial. Several previous studies demonstrated that SLR reduces the incidence of POB but provided conflicting evidence with regard to the optimal technique. In a similar analysis of an older version of MBSAQIP, Berger et al found that buttressing resulted in lower bleed rates compared with no SLR.^[@B8]^ Patients who underwent buttressing with or without oversewing of the staple line had significantly lower bleeding rates than did those patients with no reinforcement (0.67% vs 1.00%). In their analysis, they found that the bleeding rate with just oversewing was higher than that of buttress alone or buttress plus oversewing.^[@B8]^ Musella et al found that using fibrin sealant significantly reduced the rate of POB after LSG compared with no reinforcement.^[@B9]^ In a multicenter study of 1162 LSG patients, D\'Ugo et al also found a lower rate of POB in patients who received SLR with either oversewing, bovine pericardium, synthetic polyester, glycolide/trimethylene copolymer, or thrombin matrix.^[@B10]^ They found no difference between the various techniques used. However, other studies have found no benefit with SLR to prevent POB after LSG. Carandina et al found that in comparison with the non-SLR group, performing SLR with either fibrin glue coverage or oversewing with imbricating absorbable or barbed running suture did not change the rate of POB.^[@B11]^ A large meta-analysis of 7 randomized controlled trials found no significant difference in bleeding when performing staple line oversewing during LSG.^[@B12]^ Most of the studies showing no benefit for staple line treatment have smaller sample sizes and may be lacking in power to demonstrate a difference.

There may be a role for selective versus routine use of SLR. In our study, we found that patients with hypertension, a history of renal insufficiency, and the use of preoperative therapeutic anticoagulation are associated with higher odds of developing POB; these may be considered high-risk patients. We were unable to perform stratified analysis of staple line treatment in high- and low-risk patients alone due to lack of power; however, this should be considered in the future as more data are accrued. A previous study by Janik et al found that protective factors for hemorrhagic complications after LSG were no history of obstructive sleep apnea (OSA) and no history of hypertension. They also found that a low level of surgeon expertise and no SLR were associated with a higher risk of POB.^[@B13]^ De Angelis et al, in a 4-year review of a high-volume center, similarly found that patients with POB were more likely to have hypertension and to be taking anticoagulation medications.^[@B14]^ We found, somewhat comparably, that hypertension is associated with a 33% increased risk of post-LSG bleeding. Janik et al surmised that because both hypertension and OSA are associated with peripheral vascular resistance and atherosclerosis, these conditions can lead to vascular remodeling, which may change the vascular histology and increase stiffness of the small vessels. In turn, the staple firing or ligation by the energy device may have been altered as a result.^[@B13]^ Choosing to perform SLR in high-risk patients, such as patients with hypertension or OSA or who are taking anticoagulation therapy, may be the most beneficial route, rather than performing SLR routinely on all patients. Future cost-effectiveness studies should focus on high-risk individuals.

Reinforcing the staple line can require extra operative time, cost, and expertise. Carandina et al found that SLR significantly increased mean total operative time by up to about 27 min; however, it did not increase LOS.^[@B11]^ A meta-analysis found that, overall, there was no significant difference in operative time between SLR and the no-reinforcement group; however, when stratified, there was found to be a longer operative time for the oversewing group compared with no reinforcement.^[@B15]^ In a study done in Italy, Gentileschi et al found that oversewing the staple line, buttressing the transsection with a polyglycolide acid and trimethylne carbonate, or staple line roofing with gelatin fibrin matrix also increased the cost of the operation by up to 580 euros per patient. Also, mean operating room times increased by up to 14 min with the addition of SLR.^[@B16]^ However, the costs of leaks and POBare quite significant^[@B3]^ and may easily offset the cost of extra time taken to reinforce the staple line.^[@B17]^

There are several limitations to this study. Because this is a retrospective analysis of prospectively collected data, our analysis is limited to the information provided in the dataset and is subject to errors in data collection and coding inherent to large database studies. It is important to remember that our analysis captures only clinically significant bleeding events and not all postoperative bleeds. In our definition of POB, we only include those bleeding events that led to a blood transfusion or an interventional procedure. It is very possible that there are still several patients who had POB that was not clinically significant to require transfusions or procedure. Also, surgeons have varying thresholds to intervene on POB. It is impossible to capture and account for these variations in our analysis. There is no clear variable for postoperative "leaks" in the dataset, and this was not assessed. However, assessing postoperative leaks was also not in the scope of this report, which focuses on postoperative bleeds. Another limitation is that all SLR by buttressing is lumped into one category; no information is available about the product used, so product-related effects cannot be ascertained. Similarly, the particular techniques used to oversew are also unknown. In addition, individual information on facilities and surgeons is not provided in the MBSAQIP PUF, so we are unable to adjust for clustering by facility or provider.

In conclusion, POB, occurring in 0.6% of patients after LSG, can be significantly reduced by addressing the staple line. We found that either suture oversewing or buttressing the staple line with a commercial product is effective at maintaining hemostasis. More research must be done to determine the underlying reasons for postoperative staple line bleeding and whether SLR should be performed only in a selection of high-risk patients. Because POB after LSG is associated with remarkably worse outcomes, these reinforcement techniques should be strongly considered by the bariatric surgeon.
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